Company: SMNR
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001193125-25-179226
Chunk: 370

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 370
---
 do not believe that the
disclosure schedules contain information that is material to an investment decision. Additionally, the representations and warranties of the parties to the Merger Agreement may or may not have been accurate as of any specific date and do not purport
to be accurate as of the date of this proxy statement/prospectus. Accordingly, no person should rely on the representations and warranties in the Merger Agreement or the summaries thereof in this proxy statement/prospectus as characterizations of
the actual state of facts about Denali, Semnur or any other matter.

The Merger Agreement contains representations and warranties of Semnur relating to,
among other things, corporate existence and power, corporate authorization, governmental authorization, non-contravention, consents, capital structure, organizational documents, assumed names, subsidiaries,
financial statements, absence of certain changes, properties, title to Semnur’s assets, litigation, contracts, licenses and permits, compliance with laws, intellectual property, customers and suppliers, employees and employee benefit plans,
real property, tax

220

matters, environmental laws, finders’ fees, directors and officers, international trade matters, anti-briberycompliance, investment company status, compliance with health care laws and certain contracts, insurance, related party transactions and data privacy matters. The Merger Agreement contains representations and warranties of Denali and Merger Sub relating to, among other things, corporate existence and power, corporate authorization, governmental authorization, non-contravention,finders’ fees, issuance of shares, capitalization, information supplied, trust fund, listing, reporting company, no market manipulation, board approval, Denali’s SEC documents and financial statements, absence of changes, litigation, compliance with laws, money laundering laws and OFAC compliance, investment company status, tax matters, contracts, investigation and pre-signingmerger filings. None of the representations, warranties or covenants, including any rights upon breach of such representations, warranties or covenants will survive the Closing except for such covenants and agreements that by their terms expressly apply post-Closing. Material Adverse Effect Under the Merger Agreement, (i) certain representations and warranties of Denali and Semnur are qualified in whole or in part by a Material Adverse Effect standard for purposes of determining whether a breach of such representations and warranties has occurred (ii) the obligation of each of Denali and Merger Sub to consummate the Business Combination is conditioned on no Material Adverse Effect having occurred from the date of the